Bridgeway Capital Management, LLC Alpine Immune Sciences, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.89 - $9.39 $172,250 - $234,750	-25,000 Reduced 26.15%	70,611 $508,000
Q2 2022 Aug 15, 2022	SELL	$6.71 - $9.52 $335,500 - $476,000	-50,000 Reduced 34.34%	95,611 $814,000
Q4 2021 Feb 14, 2022	SELL	$10.41 - $13.95 $83,280 - $111,600	-8,000 Reduced 5.21%	145,611 $2.02 Million
Q2 2021 Aug 16, 2021	BUY	$8.81 - $15.03 $1.35 Million - $2.31 Million	153,611 New	153,611 $1.38 Million
Q2 2019 Aug 14, 2019	SELL	$4.08 - $7.75 $145,860 - $277,062	-35,750 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$3.68 - $6.07 $11,040 - $18,210	-3,000 Reduced 7.74%	35,750 $132,000
Q4 2017 Feb 14, 2018	BUY	$9.65 - $12.65 $193,000 - $253,000	20,000 Added 106.67%	38,750 $434,000
Q3 2017 Nov 14, 2017	BUY	$8.0 - $11.6 $150,000 - $217,500	18,750	18,750 $218,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.